Adma Biologics (ADMA) Assets (2011 - 2026)
Adma Biologics' (ADMA) quarterly Assets came in at $624.2 million in Q4 2025, up 27.74% YoY from $488.7 million in Q4 2024, and up 9.77% on a QoQ basis from $568.7 million in Q3 2025.
Adma Biologics (ADMA) Assets (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Assets data on file, last reported at $624.2 million in Q4 2025.
- Quarterly Assets rose 27.74% year-over-year to $624.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $624.2 million (up 27.74% YoY) and the FY2025 annual result came in at $624.2 million, up 27.74% from the prior year.
- Assets grew to $624.2 million in Q4 2025, from $568.7 million in the prior quarter.
- In the past five years, Assets ranged from a high of $624.2 million in Q4 2025 to a low of $232.8 million in Q2 2021.
- A 5-year average of $373.4 million and a median of $345.7 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2021 — Assets jumped 134.49% — and 2023, when it declined 5.53%.
- Tracing ADMA's Assets over 5 years: stood at $276.3 million in 2021, then gained by 26.14% to $348.5 million in 2022, then decreased by 5.53% to $329.2 million in 2023, then jumped by 48.45% to $488.7 million in 2024, then climbed by 27.74% to $624.2 million in 2025.
- The last three Assets figures came in at $624.2 million (Q4 2025), $568.7 million (Q3 2025), and $558.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 684.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 684.21 Mn |
| Dec 31, 2025 | 624.24 Mn |
| Sep 30, 2025 | 568.69 Mn |
| Jun 30, 2025 | 558.38 Mn |
| Mar 31, 2025 | 510.57 Mn |
| Dec 31, 2024 | 488.68 Mn |
| Sep 30, 2024 | 390.62 Mn |
| Jun 30, 2024 | 376.40 Mn |
| Mar 31, 2024 | 350.88 Mn |
| Dec 31, 2023 | 329.18 Mn |
| Sep 30, 2023 | 349.00 Mn |
| Jun 30, 2023 | 343.03 Mn |
| Mar 31, 2023 | 340.79 Mn |
| Dec 31, 2022 | 348.46 Mn |
| Sep 30, 2022 | 300.56 Mn |
| Jun 30, 2022 | 296.93 Mn |
| Mar 31, 2022 | 308.03 Mn |
| Dec 31, 2021 | 276.25 Mn |
| Sep 30, 2021 | 238.64 Mn |
| Jun 30, 2021 | 232.81 Mn |